Stock Watch: Gaming The US Health Care System
Pharmacies Should Be Held To Account For Role In Drug Price Inflation
The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.
You may also be interested in...
As stakeholders begin to mull the impact of the Arthrex opinion, HHS withdraws its advisory opinion concluding manufacturers are legally bound to provide 340B discounts to contract pharmacies, and Lilly takes aim at 340b contract pharmacy ‘replenishment’ model.
Valeant Pharmaceuticals International Inc. finally filed its 10-K with the Securities and Exchange Commission, disclosing new investigations into the firm's pricing and business practices and further details about its shady dealings with the specialty pharmacy Philidor Rx Services Inc. The company also revealed its plans to shake up its board – nominating three new members.
Are three FDA clinical holds in less than four days a symptom of lax safety programs at some biotech companies? And what does the latest publication on Aduhelm say about the relationship between safety and accelerated approval?